These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 34497201)
1. [Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan]. Sekiguchi N Rinsho Ketsueki; 2021; 62(8):1139-1148. PubMed ID: 34497201 [TBL] [Abstract][Full Text] [Related]
2. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316 [TBL] [Abstract][Full Text] [Related]
3. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report. Barnes M; Sharma P; Kumar V; Kaell A; LiPera W J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665 [TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed and refractory Waldenstrom Macroglobulinemia. Amaador K; Kersten MJ; Minnema MC; Vos JMI Leuk Lymphoma; 2023 Jan; 64(1):30-41. PubMed ID: 36282673 [TBL] [Abstract][Full Text] [Related]
5. L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma. Mori N; Ohwashi M; Yoshinaga K; Mitsuhashi K; Tanaka N; Teramura M; Okada M; Shiseki M; Tanaka J; Motoji T PLoS One; 2013; 8(11):e80088. PubMed ID: 24224040 [TBL] [Abstract][Full Text] [Related]
6. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-3. Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM). Kobayashi Y Int J Hematol; 2019 Nov; 110(5):524-528. PubMed ID: 31494831 [No Abstract] [Full Text] [Related]
11. The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia. Chin CK; Leslie C; Grove CS; Van Vliet C; Cheah CY Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28937595 [TBL] [Abstract][Full Text] [Related]
12. Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study. Brandefors L; Sander B; Lundqvist K; Kimby E Br J Haematol; 2022 Mar; 196(6):1362-1368. PubMed ID: 34959252 [TBL] [Abstract][Full Text] [Related]
13. Current approach to Waldenström Macroglobulinemia. Ravi G; Kapoor P Cancer Treat Res Commun; 2022; 31():100527. PubMed ID: 35149375 [TBL] [Abstract][Full Text] [Related]
14. Managing Waldenström's macroglobulinemia with BTK inhibitors. Buske C; Jurczak W; Salem JE; Dimopoulos MA Leukemia; 2023 Jan; 37(1):35-46. PubMed ID: 36402930 [TBL] [Abstract][Full Text] [Related]
15. How to manage waldenström's macroglobulinemia in 2024. Grunenberg A; Buske C Cancer Treat Rev; 2024 Apr; 125():102715. PubMed ID: 38471356 [TBL] [Abstract][Full Text] [Related]